Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-cont... by Ledermann, J.A., Zurawski, B., Raspagliesi, F., De Giorgi, U., Arranz Arija, J., Romeo Marin, M., Lisyanskaya, A., Póka, R.L., Markowska, J., Cebotaru, C., Casado Herraez, A., Colombo, N., Kutarska, E., Hall, M., Jacobs, A., Ahrens-Fath, I., Baumeister, H., Zurlo, A., Sehouli, J.

Get full text

CA-125 as a response marker for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: The PRECEDENT trial by Bidzinski, M, Lovejoy, C, Anderson, K, Rangwala, R, Kutarska, E

Get full text

Adverse event profile by folate receptor status for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer by Kutarska, E, Bidzinski, M, Symanowski, J, Nguyen, B, Rangwala, R, Naumann, R.W

Get full text

2731 Impact of frailty on outcome of elderly patients treated with hormone therapy for advanced/recurrent endometrial cancer (EC) by Joly, F, Pautier, P, Vergote, I, Melichar, B, Kutarska, E, Hall, G, Lisayankaya, A, Reed, N, Oaknin, A, Ostapenko, V, Zvirbule, Z, Chetaille, E, Shoaib, M, Green, J.A, Heutte, N

Get full text

5001 ORAL Intraperitoneal administration of the trifunctional antibody catumaxomab for treatment of malignant ascites due to ovarian carcinoma: Results of a phase II/III study by Parsons, S, Kutarska, E, Koralewski, P, Gore, M, Wimberger, P, Burges, A, Sroehlein, M.A, Friccius-Quecke, H, Jaeger, M, Heiss, M.M

Get full text